These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16106597)

  • 41. Why drugs get pulled off the market.
    Meadows M
    FDA Consum; 2002; 36(1):11-7. PubMed ID: 11881590
    [No Abstract]   [Full Text] [Related]  

  • 42. Metabolites in safety testing: "MIST" for the clinical pharmacologist.
    Frederick CB; Obach RS
    Clin Pharmacol Ther; 2010 Mar; 87(3):345-50. PubMed ID: 20107437
    [No Abstract]   [Full Text] [Related]  

  • 43. The risks of methodology aversion in drug regulation.
    Bauer P; König F
    Nat Rev Drug Discov; 2014 May; 13(5):317-8. PubMed ID: 24781535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of numbers and timing of new medication regulatory approvals in Canada and New Zealand.
    Rawson NSB
    Regul Toxicol Pharmacol; 2019 Feb; 101():24-28. PubMed ID: 30391284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The origins of new drugs.
    Kneller R
    Nat Biotechnol; 2005 May; 23(5):529-30. PubMed ID: 15877061
    [No Abstract]   [Full Text] [Related]  

  • 46. Drug withdrawals from the Canadian market for safety reasons, 1963-2004.
    Lexchin J
    CMAJ; 2005 Mar; 172(6):765-7. PubMed ID: 15767610
    [No Abstract]   [Full Text] [Related]  

  • 47. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 48. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 2008 FDA drug approvals.
    Hughes B
    Nat Rev Drug Discov; 2009 Feb; 8(2):93-6. PubMed ID: 19180096
    [No Abstract]   [Full Text] [Related]  

  • 50. Letter: Introduction of "new" drugs.
    Morrison AB
    Can Med Assoc J; 1975 Jun; 112(11):1285, 1289. PubMed ID: 1125900
    [No Abstract]   [Full Text] [Related]  

  • 51. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 53. [Increased significance of adverse effects of drugs--a threat to the industry].
    Werkö L
    Lakartidningen; 2004 Dec; 101(50):4134-6. PubMed ID: 15631270
    [No Abstract]   [Full Text] [Related]  

  • 54. Drugs used in pregnancy: the regulatory process.
    Tomalin A
    Can J Clin Pharmacol; 2007; 14(1):e5-9. PubMed ID: 17213510
    [No Abstract]   [Full Text] [Related]  

  • 55. FDA new drug approvals in 2003.
    Wynn RL
    Gen Dent; 2004; 52(4):294-8, 300. PubMed ID: 15366292
    [No Abstract]   [Full Text] [Related]  

  • 56. New drugs of 1996.
    Hussar DA
    J Am Pharm Assoc (Wash); 1997; NS37(2):192-228; quiz 228-32. PubMed ID: 9069693
    [No Abstract]   [Full Text] [Related]  

  • 57. [Safe drugs for children].
    Krankenpfl J; 2004; 42(7-10):230. PubMed ID: 15675392
    [No Abstract]   [Full Text] [Related]  

  • 58. Cell and tissue therapy regulation: worldwide status and harmonization.
    Kellathur SN; Lou HX
    Biologicals; 2012 May; 40(3):222-4. PubMed ID: 22374355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
    Doshi A
    Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
    [No Abstract]   [Full Text] [Related]  

  • 60. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.